Sonnet BioTherapeutics Holdings Inc
SONN
Company Profile
Business description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Contact
100 Overlook Center
Suite 102
PrincetonNJ08540
USAT: +1 609 375-2227
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
13
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,207.30 | 32.70 | -0.35% |
| CAC 40 | 7,683.85 | 159.19 | -2.03% |
| DAX 40 | 24,163.36 | 109.76 | -0.45% |
| Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
| FTSE 100 | 9,266.93 | 54.47 | -0.58% |
| HKSE | 25,524.92 | 304.99 | -1.18% |
| NASDAQ | 21,449.29 | 47.24 | -0.22% |
| Nikkei 225 | 42,394.40 | 413.42 | -0.97% |
| NZX 50 Index | 12,957.98 | 121.52 | -0.93% |
| S&P 500 | 6,439.32 | 27.59 | -0.43% |
| S&P/ASX 200 | 8,935.60 | 31.30 | -0.35% |
| SSE Composite Index | 3,868.38 | 15.18 | -0.39% |